NCT02368691终止2 期
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- GTx
- 入组人数
- 32
- 试验地点
- 7
- 主要终点
- Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects
研究概览
简要总结
The purpose of this study is to determine if GTx-024 is effective and safe in the treatment of patients with advanced, androgen receptor positive triple negative breast cancer (AR+ TNBC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Able and willing to give voluntary, written and signed, informed consent
- •Women ≥ 18 years of age
- •Women with TNBC who have received at least one but no more than two prior chemotherapy regimens for TNBC
- •Confirmation of AR+ (defined as ≥ 10% nuclear AR staining by immunohistochemistry [IHC]) TNBC in either the primary or metastatic lesion, assessed during the screening period by a local laboratory or by medical history
- •TNBC confirmed by medical history as: human epidermal growth factor receptor 2 [HER2]-negative (confirmed by IHC 0, 1+ regardless of fluorescence in situ hybridization [FISH] ratio; IHC 2+ with FISH ratio lower than 2.0 or HER2 gene copy less than 6.0; FISH ratio of 0, indicating gene deletion, when positive and negative in situ hybridization [ISH] controls are present); estrogen receptor (ER) negative (confirmed as ER expression less than or equal to 1% positive tumor nuclei); progesterone receptor negative (confirmed as progesterone receptor expression less than or equal to 1% positive tumor nuclei)
- •Availability of paraffin embedded or formalin fixed tumor tissue; OR, a minimum of 10 and up to 20 slides of archived tumor tissue for central laboratory confirmation of AR status and molecular subtyping. Metastatic tumor tissue is preferred when possible
- •Subjects must have either measurable disease or bone-only non-measurable disease, evaluable according to RECIST 1.1
- •Subjects with bone metastases should be treated with intravenous bisphosphonates or subcutaneous denosumab (or investigator preferred standard of care) prior to and during the trial, unless there is a contraindication or subject intolerance to these therapies
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the time of screening and enrollment
- •Negative pregnancy test in women of childbearing potential (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization), no more than 7 days before the first dose of study treatment
- •For women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of contraception during and for at least 6 months after completion of study treatment; OR, a fertile male partner willing and able to use effective non-hormonal of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilization) during and for at least 6 months after completion of study treatment
- •Adequate organ function as shown by:
- •Absolute neutrophil count ≥ 1,000 cells/mm3
- •Platelet count ≥ 100,000 cells/mm3
- •Hemoglobin ≥ 9 g/dL
- •Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 Upper Limit of the Normal range (ULN) (or ≤ 5 if hepatic metastases are present)
- •Total serum bilirubin ≤ 2.0 × ULN (unless the subject has documented Gilbert Syndrome)
- •Alkaline phosphatase levels ≤ 2.5 × ULN (≤ 5 × ULN in subjects with liver metastasis)
- •Serum creatinine < 2.0 mg/dL or 177 μmol/L
- •International normalized ratio (INR), activated partial thromboplastin time (aPTT), or partial thromboplastin time (PTT) < 1.5 × ULN (unless on anticoagulant treatment at screening)
- •Able to swallow capsules
- •Any toxicity from prior chemotherapy has resolved or Grade 1 (NCI-CTCAE, Version 4.0)
排除标准
- •Life expectancy < 4 months;
- •Subjects with radiographic evidence of central nervous system (CNS) metastases as assessed by computerized tomography (CT) or magnetic resonance imaging (MRI) that are not well controlled (symptomatic or requiring control with continuous corticosteroid therapy [e.g., dexamethasone]). Note: Subjects with CNS metastases are permitted to participate in the study if the CNS metastases are medically well controlled prior to screening (as assessed by the Investigator) after receiving local therapy (irradiation, surgery, etc.)
- •Radiotherapy within 14 days prior to first dose of study treatment
- •Have, in the judgment of the Investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical, or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
- •Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening
- •Positive human immunodeficiency virus (HIV) infection at screening
- •Prior treatment with any anti-androgens, including but not limited to, enzalutamide and bicalutamide
- •Major surgery within 28 days of the first dose of study treatment
- •Be currently taking or have previously taken testosterone, methyltestosterone, oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), or anti-androgens
- •Treatment with any of the following hormone replacement therapies, unless discontinued at least 14 days prior to the first dose of study treatment:
- •Estrogens
- •Megesterol acetate
- •Treatment with any investigational agent within 28 days before the first dose of study treatment
- •Another active cancer (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed as long as there is no active disease within the prior 5 years
- •Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator, such as but not limited to:
- •Myocardial infarction or arterial thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTcB (corrected according to Bazett's formula) interval > 470 msec; serious uncontrolled cardiac arrhythmia grade II or higher according to NYHA; uncontrolled hypertension (systolic > 150 and/or diastolic > 100 mm Hg)
- •Acute and chronic active infectious disorders and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy
- •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
- •Current treatment with intravenous bisphosphonate or denosumab with elevated serum calcium corrected for albumin or ionized calcium levels outside institutional normal limits at screening
- •History of non-compliance to medical regimens
- •Subjects unwilling to or unable to comply with the protocol procedures as assessed by the Investigator
- •Concurrent participation in another therapeutic clinical trial
研究组 & 干预措施
GTx-024
Experimental
GTx-024 capsules, 18 mg PO once-daily for up to 12 months
干预措施: GTx-024 (Drug)
结局指标
主要结局
Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects
时间窗: Sixteen (16) weeks
To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST) as assessed by CT or MRI in subjects with centrally confirmed AR+ status. Clinical Benefit Rate=CR+PR+SD. Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, \<30% decrease in sum of the longest diameter of target lesions.
次要结局
- Best Overall Response(From treatment initiation to end of treatment (up through 11 months of treatment, median duration of treatment 1.9 months).)
- Time-to-progression(From treatment initiation to tumor progression or death. Time to progression was assessed up to 11 months of treatment; median duration of treatment, 1.9 months)
- Clinical Benefit Rate, in Full Analysis Set(Sixteen (16) weeks)
- Progression Free Survival(From treatment initiation to tumor progression or death. PFS was assessed up to 11 months of treatment; median duration of treatment, 1.9 months)
- Duration of Response(From time of documented tumor response to tumor progression or death. Duration of response was assessed through 11 months; median treatment duration, 1.9 months)
- Objective Response Rate(Sixteen (16) weeks)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast CancerER+ and AR+ Breast CancerNCT02463032GTx136
已完成
3 期
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumMuscle WastingNon-Small Cell Lung CancerNCT01355497GTx330
已完成
3 期
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)Muscle WastingNon Small Cell Lung CancerNCT01355484GTx321
Unknown
2 期
Efficacy and Safety of GHX02 in the Treatment of Acute BronchitisAcute BronchitisNCT03310385Daejeon University150
已完成
1 期
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)NCT05364424Hoffmann-La Roche43